Option chain shows key data for Sonnet BioTherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Sonnet BioTherapeutics.

Sonnet BioTherapeutics (NASDAQ:SONN) Stock, Option Chain

Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Box,Headquarters,In,Redwood,City,,California,,Usa,-,June,8,

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BROG

CETX

CODI

GLXY

IFRX

IMNN

JFBR

JOBY

LAES

LVWR

NEHC

OKTA

PMAX

SGBX

SONN

WORX

Why Box Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

Record High Gold Prices

Earnings

Equities

Eurozone

Commodities

CTKB

NOVA

PACS

TMCI

ZCAR

Gold Down Over 2%; CVS Health Shares Jump After Q3 Results

5 Things Moving As Trump Trade Fever Sweeps Wall Street Amid Election Night Drama

Intraday Update

FOXO

Dow Jumps Over 1,200 Points; Donald Trump Wins White House

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics Holdings Inc

Health Care

Press Releases

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Management

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

General

Sonnet Announces Release of Corporate Update Video

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Sonnet Releases Virtual Investor "What This Means" Segment

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

MBRX

Aditxt

Apollomics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Galecto

GRI Bio

Mustang Bio

Moleculin Biotech

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Polyrizon

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

SILO Pharma

Soligenix

Tharimmune

Theriva Biologics

VivoSim Labs

Longevity Health Holdings, Inc. - Common Stock

Longevity Health Holdings

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Chardan Capital

EF Hutton

Ladenburg Thalmann

Comments

Sonnet BioTherapeutics

Sonnet BioTherapeutics (SONN) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell